撤回药品注册申请，凯因科技大跌13.23%

Core Viewpoint - Kaiyin Technology (688687) experienced a significant decline of 13.23%, closing at 22.76 CNY per share following the announcement of the termination of its drug registration application for Pegylated Interferon α-2 Injection (new hepatitis B indication) by the National Medical Products Administration (NMPA) [1] Group 1 - The company received a notice from the NMPA approving the termination of its drug registration application [1] - The decision to withdraw the application was made after careful consideration of the NMPA's latest review suggestions [1] - The company plans to supplement clinical case studies as required by the NMPA and may resubmit the registration application in the future [1] Group 2 - The company has fully recognized an asset impairment provision for the development expenses related to the Pegylated Interferon α-2 Injection project, which will reduce the company's total profit for 2025 by 111.3011 million CNY [1]